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Abstract
Background: Both overt hypothyroidism as well as minor elevations of serum thyrotropin (TSH) levels associated
with thyroid hormones within their respective reference ranges (termed subclinical hypothyroidism) are relatively
common in older individuals. There is growing evidence that treatment of subclinical hypothyroidism may not be
beneficial, particularly in an older person. These findings are relevant at a time when treatment with thyroid hormones
is increasing and more than 10–15% of people aged over 80 years are prescribed levothyroxine replacement therapy.
Main body: The prevalence of hypothyroidism increases with age. However, the reference range for TSH also rises
with age, as the population distribution of TSH concentration progressively rises with age. Furthermore, there is evidence
to suggest that minor TSH elevations are not associated with important outcomes such as impaired quality of life,
symptoms, cognition, cardiovascular events and mortality in older individuals. There is also evidence that treatment of
mild subclinical hypothyroidism may not benefit quality of life and/or symptoms in older people. It is unknown whether
treatment targets should be reset depending on the age of the patient. It is likely that some older patients with non-
specific symptoms and incidental mild subclinical hypothyroidism may be treated with thyroid hormones and could
potentially be harmed as a result. This article reviews the current literature pertaining to hypothyroidism with a special
emphasis on the older individual and assesses the risk/benefit impact of contemporary management on outcomes in this
age group.
Conclusions: Current evidence suggests that threshold for treating mild subclinical hypothyroidism in older people
should be high. It is reasonable to aim for a higher TSH target in treated older hypothyroid patients as their thyroid
hormone requirements may be lower. In addition, age-appropriate TSH reference ranges should be considered in the
diagnostic pathway of identifying individuals at risk of developing hypothyroidism. Appropriately designed and powered
randomised controlled trials are required to confirm risk/benefit of treatment of subclinical hypothyroidism in older
people. Until the results of such RCTs are available to guide clinical management international guidelines should be
followed that advocate a conservative policy in the management of mild subclinical hypothyroidism in older individuals.
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Background
The population of the world is ageing. In the United
Kingdom, nearly one in seven people is projected to be
aged over 75 years by the year 2040. [1] However,
increases in health life expectancy measured at 65 and 85
are not keeping pace with improvements in numerical life
expectancy. This suggests that real health improvements
are being experienced by younger people, and that people
over 65 years of age are spending more time in ill-health.
Therefore, unless this trend can be reversed, a major chal-
lenge for an ageing population is likely to be an increasing
prevalence of the health conditions associated with old
age such as dementia, type 2 diabetes mellitus and cardiac
diseases. Apart from the effects on individuals and their
families, this demographic change will have major socio-
economic and political implications.
Thyroid hormones have a major influence on all major
organs/systems and adequate levels are important for opti-
mal function. Thyroid dysfunction is a common condition
that affects between 3 and 21% of the population with
prevalence being more common in women and in older in-
dividuals. [2] In the UK, it is estimated that hypothyroidism
treated with levothyroxine may affect nearly 800,000 older
individuals aged more than 70 years. [3] The clinical
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presentation of thyroid dysfunction is non-specific and
often variable; therefore, the diagnosis of thyroid dysfunc-
tion is based primarily on biochemical abnormalities. The
pituitary hormone thyrotropin (TSH) has a complex inverse
relationship with the thyroid hormones thyroxine (T4) and
tri-iodothyronine (T3). A negative feedback mechanism ex-
ists between TSH and thyroid hormones, which means that
TSH levels are the most sensitive marker of thyroid status
in an individual. [4] Accordingly, overt hypothyroidism is
defined as serum TSH concentrations above the reference
range with low free T4 levels, while subclinical hypoth
yroidism is diagnosed when TSH levels are high and circu-
lating free T4 is normal. The relationship between TSH
and thyroid hormones is influenced by a number of factors
including age, smoking and thyroid peroxidase antibody
status. [5] Recent data from observational studies suggest
that serum TSH levels increase in older people. [6] Thus,
very mild TSH elevations in older individuals may not re-
flect subclinical thyroid dysfunction but rather be a normal
consequence of ageing. Besides, serum TSH levels are also
influenced by genetic, environmental, clinical and thera-
peutic factors and agents, as well as trends in clinical prac-
tice [7]. Despite this, adult patients are often managed
similarly utilising a uniform serum TSH reference range
(usually 0.4–4.5mU/L) and age-specific ranges are not in
routine clinical use. In addition, thyroid hormone require-
ments change with age and older patients on replacement
therapy are more susceptible to the effects of thyroid hor-
mone excess such as osteoporosis and atrial fibrillation.
Therefore, careful consideration is required in the interpret-
ation of thyroid function test results as well as in managing
thyroid disease in the older population. The interest in
thyroid function in the elderly has been increasing with the
recognition that thyroid status is may be linked to disability,
cognitive function, cardiovascular disease risk and
longevity.
This review describes the prevalence of hypothyroidism
in the older population and outlines the effects of treat-
ment in this age group.
Main text
Prevalence of hypothyroidism in the elderly
Hypothyroidism is more prevalent in older individuals.
The Whickham survey was the first population-based
study to evaluate the presence of thyroid dysfunction in
community-dwelling individuals. This seminal study ob-
served that TSH levels increased with age in women after
the age of 45 years but the same phenomenon was not seen
in men. [8] The main limitation of the Whickham study,
however, was that it utilised the first-generation TSH assay
available at that time and was therefore unable to reliably
detect TSH levels lower than 1.0mU/L. Subsequently, a
number of cross-sectional studies have been performed
across various geographical locations and studying various
age groups. In the studies restricted to older persons, the
reported prevalence of overt hypothyroidism has ranged
between 0.2–5.7% and subclinical hypothyroidism between
1.5–12.5%. [9–20] Some of the main prevalence studies are
outlined in Table 1. The wide variation between the various
studies probably reflects the disparate nature of the popu-
lations being assessed with regards to their gender, iodine
intake, age-groups, racial groups and treated thyroid dis-
ease prevalence. For example, the Zoetermeer study from
the Netherlands reported the lowest prevalence of subclin-
ical hypothyroidism of just 1.5%, most likely due to the
inclusion of only men in this analysis. [19]
As the TSH distribution and the reference limits shift to
higher concentrations with age, the prevalence of subclin-
ical hypothyroidism may be overestimated. Employing a
uniform TSH reference range across all age groups in the
NHANES study led to approximately 70% of older individ-
uals with a slightly high serum TSH being incorrectly
classed as having subclinical hypothyroidism. [21] An ana-
lysis of TSH results from one pathology centre in Western
Australia however concluded that the use of age-specific
TSH reference ranges has minimal impact on reclassifying
thyroid status except in the very old (85 years), in whom
2–4.7% were reclassified as being euthyroid. [22] The
reference ranges for TSH are discussed in the next section
in more detail.
TSH reference range in the elderly
Biochemical testing of thyroid function is fundamental to
establish a diagnosis of thyroid dysfunction including
hypothyroidism. The tests include measurement of circulat-
ing TSH and thyroid hormones in the serum. Assays for
estimating serum TSH have improved vastly over the last
few decades and the current immunoassays have the ability
to detect very low levels (less than 0.1mU/L). On the other
hand, the reference range for thyroid hormones is wide for
a given population, therefore, in principle, TSH will be the
first detected circulating abnormality as the pituitary regis-
ters that T4 has changed from its genetically determined
setpoint for that particular individual. [24] Thus, TSH
measurement has now been firmly established as the
first-line thyroid function test to assess thyroid status in the
vast majority of patients with suspected thyroid disease.
[25, 26] However, it is important to remember that meas-
urement of serum TSH is only reliable for diagnosing
thyroid function abnormalities provided that patients are
not receiving drug therapies that alter TSH secretion or
have pituitary disease. Measurement of serum TSH is also
considered to be the key thyroid function test for diagnos-
ing early (also called mild or subclinical) hypo- or hyperthy-
roidism because of the log-linear relationship between TSH
and T4: a twofold change in serum FT4 level leads to a
100-fold alteration in circulating TSH. [27]
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The American National Academy of Clinical Biochemis-
try formulated guidelines in 2003 which state that “TSH
reference intervals should be established from the 95%
confidence limits of the log-transformed values of at least
120 rigorously screened normal euthyroid volunteers who
have: (a) No detectable thyroid autoantibodies, TPOAb or
TgAb (measured by sensitive immunoassay); (b) No
personal or family history of thyroid dysfunction; (c) No
visible or palpable goitre and, (c) Who are taking no medi-
cations except oestrogen”. [28] In addition, TSH secretion
has a diurnal variation with a peak late at night/early hours
of morning, and, therefore, sample timing and shift work
should also be considered when defining the TSH refer-
ence range. [29] In the last few decades, the ability of the
TSH assays to detect lower levels has improved with each
generation and therefore the present lower euthyroid
reference limit is set at 0.3–0.5mU/L. This has resulted in
subclinical hyperthyroidism being diagnosed with much
greater precision, irrespective of the population being stud-
ied or the method used. In contrast, the upper (97.5 per-
centile) reference limit for nonpregnant adults is still not
universally agreed. [30, 31] As a consequence, the diagnosis
of subclinical hypothyroidism is still very much dependent
on the value at which the upper limit of TSH is set.
The TSH reference range should also consider the
intra-individual variability of the TSH measurement.
Several studies provide data showing significant variation
in repeated TSH measurements over time in the same
individuals. [27] Each person has a specific and unique set-
point for thyroid hormone concentrations, which is partly
genetically determined, as shown by twin studies. [24] TSH
measurements in an individual vary within 50% of the en-
tire group’s TSH distribution, with a large and clinically
significant variation. [32] TSH levels are also known to
increase with age when checked over many years. In both
the Cardiovascular Health Study as well as the Busselton
Health study, there was a significant rise in TSH levels with
little or no change in FT4 levels over a 13-year period. [33,
34] This finding, however, was not confirmed in the
Rotterdam study in which TSH levels remained stable over
a 6.5-year interval whereas FT4 levels increased. [10] An
analysis from the Baltimore Longitudinal Study of Aging
has revealed that changes in thyroid function tests are
common, especially in older age groups, and regression to
the mean is partly responsible for this finding. Importantly,
changes in both TSH and FT4 over a 7-year period were
associated with increased mortality. [35]
The most robust data determining the TSH reference
range was obtained from the US National Health and
Nutritional Examination Survey (NHANES) III study.
[36] This large study (n = 16,088), designed to be repre-
sentative of the US general population, analysed the me-
dian and lower and upper reference limits of serum TSH
in carefully selected euthyroid individuals using current
immunoassays. This study concluded that establishing
an accurate TSH upper limit at an individual level from
population data is not possible, as TSH has a low
individuality index (the ratio between the within- and
between-person variability). The overall reference range
was deemed to be 0.4–4.1 U/L but there were significant
differences between age groups and races. For example,
the upper limit of TSH was 3.5 mU/L in the 20–29-year
Table 1 Prevalence of hypothyroidism (both overt and subclinical) in older population-based cross-sectional studies
Study [reference] Place Sample size Population studied Age range (years) Measurement of
thyroid function
Prevalence (%) Overt
Subclinical Hypothyroidism
Framingham [9] USA 2139 Both sexes > 60 TSH & T4 2.5 7.9
Rotterdam [10] Netherlands 10,318 Both sexes ≥ 45 TSH & FT4 0.8 9.1
Nagasaki [13] Japan 2550 Atomic bomb
survivors of both
sexes
58.5* TSH & FT4 NR 10.1
Cardiovascular Health S
tudy [14]
USA 3233 Both sexes > 65 TSH & FT4 1.6 15.0
Health ABC [15] USA 2730 Both sexes 70–79 TSH & FT4 0.8 12.4
Zoetermeer [19] Netherlands 403 Men only 73–94 TSH, FT4, FT3, rT3 0.2 1.5
Leiden 85+ [16] Netherlands 558 Both sexes 85 TSH & FT4 7 5.0
Birmingham [17] England 5960 Both sexes ≥ 65 TSH & FT4 0.4 2.9
Sau Paulo Ageing
and Health Study [11]
Brazil 1373 Both sexes ≥ 65 TSH, FT4 5.7 6.5
Newcastle 85+ [18] England 643 Both sexes 85 TSH, FT4, FT3, rT3 0.9 12.5
Longitudinal Aging
Study [20]
Netherlands 1219 Both sexes ≥ 65 TSH NR 5.3
InChianti study [23] Italy 951 Both sexes ≥ 65 TSH, FT4, FT3 0.5 3.0
*Mean age provided as minimum age not available
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olds but increased to 7.9 mU/L in the 80+ year group.
Similarly, the upper TSH level was 4.2 mU/L in White
people whereas it was 3.4 mU/L in Black people. Similar
data obtained from a Scottish laboratory database con-
firms an age-related increase in the upper reference limit
for serum TSH). [37] An illustration of age-specific TSH
reference ranges are described in the Fig. 1.
Serum TSH is not normally distributed and has a skew
to the right. However, more than 95% of healthy euthyroid
individuals have serum TSH values between 0.4 and 2.5
mU/L. It is therefore argued that TSH values > 2.5mU/L
reflect underlying autoimmune thyroid disease and con-
tribute to the skewed TSH distribution curve, [38] a view
further supported by the fact that such individuals have a
higher risk of progression to subsequent hypothyroidism.
[39, 40] The opposing argument to retain the upper limit
of the TSH reference range around the 4.0–5.0 mU/L
mark is that reducing the upper TSH reference limit
would lead to a vast increase in the number of people
diagnosed with subclinical hypothyroidism without any
evidence-based justification or proof of benefits of treat-
ment. [31] This issue is complicated by the concern that
current TSH immunoassays differ in specificity for recog-
nizing circulating TSH isoforms and that this can give rise
to a full 1.0 mU/L difference in TSH values reported by
different assays.
In summary, the current upper limit of the serum
TSH reference range in older people does not reflect
age-related changes and leads to the over-diagnosis of
hypothyroidism and, consequentially, the probable
unnecessary treatment of an unknown number of people
with thyroid hormones. The adoption of a universal
TSH range across all adult age groups on an individual’s
health have not been tested in prospective trials, and
unnecessary treatment will lead to a higher health and
economic burden. In addition, a slightly higher serum
TSH level may be normal in older individuals and not
associated with worse outcomes. [18, 33] This has impli-
cations for diagnosing subclinical hypothyroidism in the
elderly and also the level of serum TSH to aim for in
treated hypothyroid patients in this age group. [41]
Therefore, it has been suggested that age-specific refer-
ence limits should be utilised instead. [42] However,
further research is required before age-specific TSH ref-
erence ranges become part of routine clinical practice.
Consequences of overt and subclinical hypothyroidism in
the elderly
Symptoms
The presentation of overt hypothyroidism in the older
person is varied, non-specific, and often insidious. The
classic symptoms of hypothyroidism are less likely to be
Fig. 1 Distribution of serum Thyrotropin (TSH) in relation to age. The lower and upper limits of the TSH reference range are calculated from the
2.5th and 97.5th percentile, respectively, and the circle signifies the median value. (adapted from reference [37])
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evident in the elderly population, and if present, these
symptoms are more likely to be misattributed to either
co-morbid conditions or a manifestation of the ageing
process. [43] Older people with hypothyroidism report
fewer symptoms compared to younger counterparts. [44,
45] A prospective study comparing the frequency of re-
ported symptoms has indicated that hypothyroid patients
≥70 years are significantly less likely to report weight gain,
muscle cramps or cold intolerance than hypothyroid pa-
tients < 50 years of age. [45] A study comparing patients
with overt autoimmune hypothyroidism against matched
euthyroid controls found that whilst younger patients were
more likely to report all 13 of the surveyed symptoms of
hypothyroidism than their euthyroid controls, for older
patients only three of the thirteen symptoms (tiredness,
shortness of breath, wheezing) were more prevalent in the
hypothyroid group than in the control group. The study
used receiver operating characteristic (ROC) analyses to
assess the discriminatory ability of a symptom score in the
prediction of hypothyroidism, and whilst they identified
that this was an excellent tool for predicting hypothyroid-
ism in young men (with an area under the ROC curve of
91%; 95% CI 82–99.8%), it was poor in evaluating older
women (area under the ROC curve of 64%; 95% CI 54–
75%). [44] The non-specific and subtle presentation of
hypothyroidism in older people is further evidenced by the
studies into the screening for hypothyroidism in the older
population, which have shown only a minority of patients
with confirmed biochemical overt hypothyroidism have
symptoms suggestive of the disease. [46, 47]
Whilst it is apparent that for most older patients the
presentation of hypothyroidism is both more subtle and
less discriminatory than in younger populations, there is
however also an increased risk of the most severe presenta-
tion of hypothyroidism in the population: myxoedema
coma. [48] Manifesting with multisystem failure with clin-
ical features including reduced consciousness, hypothermia,
hypotension, bradycardia, hyponatremia, hypoglycaemia,
and hypoventilation, this is a condition with very high mor-
bidity and mortality. However, myxoedema coma is a rare
manifestation of hypothyroidism: an analysis of a Japanese
national inpatient database estimated an annual incidence
of 1.08 per million population. [48] Symptoms are largely
absent or very subtle in older patients with subclinical
hypothyroidism. In the subclinical hypothyroid group as a
whole, most patients are asymptomatic or report only
non-specific symptoms. [49, 50]
Thus, symptoms of hypothyroidism are sparse and
non-specific in older people. This leads to thyroid function
tests being frequently requested. However, due to the
uniform TSH reference range being applied across all age
groups, a substantial number of individuals are being de-
tected with mild subclinical hypothyroidism. The median
level of TSH at which treatment with thyroid hormones is
being commenced has been falling recently although the
evidence of benefit is sparse. [51]
Cardiovascular manifestations
The cardiovascular system is a major target of thyroid
hormone action and sensitive to small changes in
thyroid hormone concentrations. [52] A number of ob-
servational studies have suggested that even slight reduc-
tions in thyroid hormones are associated with higher
risk of cardiovascular disease. [53]
Meta-analyses of observational studies have shown that
subclinical hypothyroidism is related to an increased risk
of ischaemic heart disease only in younger individuals and
not in older populations. [54, 55] However, an individual
patient meta-analysis of more than 55,000 participants
contributing more than 500,000 person-years of follow-up
concluded that age does not influence the relationship
between subclinical hypothyroidism and coronary heart
disease events nor mortality. [15]
Thyroid hormones have an inotropic effect on cardiac
muscle. [56] Accordingly, some studies have shown a
positive association between hypothyroidism and heart
failure. [15] An individual participant data meta-analysis
of 25,390 participants revealed that both low as well as
high serum TSH levels. [57] In stratified analysis, there
was a trend towards lower risk of heart failure in older
individuals with subclinical hypothyroidism although
this did not reach statistical significance.
The relationship between hypothyroidism and stroke has
not been completely elucidated. A meta-analysis of individ-
ual participant data obtained from nearly half a million
person-years of follow up demonstrated no overall effect of
subclinical hypothyroidism on stroke although a signifi-
cantly higher risk was observed in participants younger
than 65 years and those with higher serum TSH levels. [58]
In a longitudinal analysis of participants from the
Rotterdam study, the risk of sudden cardiac death was
found to be higher with higher FT4 levels, even within
the reference range. [10] In age-stratified analysis, the
risk of sudden cardiac death appeared to be particularly
higher in older individuals (> 65 years) with higher FT4
levels or lower TSH concentrations.
Older individuals (> 65 years) with subclinical or overt
hypothyroidism were not observed to have adverse cardio-
vascular risk factors such as higher body mass index, in-
creased LDL cholesterol, and prevalence of hypertension or
diabetes mellitus in the Cardiovascular Health Study. [14]
Cognition
The relationship between overt hypothyroidism and cogni-
tive impairment, depression and other psychiatric manifes-
tations has been long-considered. The term ‘myxoedema
madness’ was coined to describe the constellation of confu-
sion, disorientation and psychosis that was observed to
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occasionally accompany profound hypothyroidism. [59]
These early observations were later supplemented by
physiological studies which showed alterations in electroen-
cephalograms, cerebral blood flow, and visual evoked po-
tentials in hypothyroid patients. [60, 61] Hypothyroidism
has been shown to be associated in non-demented older
adults with impairments in a variety of neuropsychological
tests of learning, word fluency, visual-spatial abilities, and
mental status. [62, 63]
Whilst hypothyroidism has classically been described as a
cause of ‘reversible dementia’, there is a lack of evidence to
show that there is complete resolution of neurocognitive
deficits following treatment of hypothyroidism. [64] Further
research is required to elucidate the potential role of pertur-
bations of thyroid function as a contributor to a dementing
process, as many of the studies to date have not been able
to adequately address that hypothyroidism, co-morbidity,
polypharmacy and alternative causes of dementia are all
common in the elderly, and that interpreting the potential
interplay between these factors is complex. [65]
In subclinical hypothyroidism, a number of studies have
shown association with adverse cognitive function in youn-
ger individuals, [66–68] but results in older people have
been conflicting. One study in individuals with a mean age
of 74 years showed that people with subclinical
hypothyroidism had worse performance on verbal recall
and cognitive scores but working memory and processing
speed were unaffected. [69] The PAQUID survey of individ-
uals aged 65 years or more showed that increased TSH
levels were significantly linked with the presence of symp-
toms of depression but not with impairment of cognitive
function. [70] There have been other studies which do not
support any association between subclinical hypothyroid-
ism and cognitive impairment. [20, 62, 71, 72] The InCH
IANTI study found a significant association between
subclinical hyperthyroidism and cognitive impairment as
assessed by the mini-mental state examination, but no such
association with subclinical hypothyroidism. [12] A pro-
spective observational study within the Leiden 85+ cohort,
which followed up a total of 599 patients from the age of
85 to 89 years for a mean period of 3.7 years, found no sig-
nificant association between thyroid dysfunction and either
depression or cognitive impairment. This was a large and
appropriately powered study, and the authors argue that in
this very elderly cohort, whilst depression, dementia and
thyroid dysfunction are all relatively common, the relation-
ship appears coincidental rather than causal. [16] In
contrast, in a notably younger cohort of predominantly
euthyroid patients aged 49–71 years, a higher TSH level
was associated with poorer performance in tests of mem-
ory. [19] Amongst the many as-yet unanswered questions
about the relationship between thyroid status and cognitive
ability, includes the possibility that the nature of this
relationship changes with the aging process.
Studies which have addressed whether cognitive func-
tioning improves with levothyroxine therapy in the context
of subclinical hypothyroidism have returned conflicting
results. Two small randomised controlled trials, recruiting
between 19 and 37 patients respectively, have reported im-
provements in cognitive function with thyroid replacement
therapy in subclinical hypothyroidism. [73, 74] However,
two larger randomised controlled trials, including the Bir-
mingham elderly thyroid study which enrolled 94 patients
over the age of 65 years, showed no improvement with
therapy. [49, 75]
Mobility and frailty
Higher TSH levels and subclinical hypothyroidism have
been associated with a variety of improved health outcomes
in the elderly population, including in domains pertinent to
the considerations of mobility and frailty. Amongst the very
elderly, there is evidence from the Newcastle 85+ study that
lower TSH levels correlate with an increasing burden of
nonthyroidal disease and disability. [18] Indeed, there is
evidence from the Health ABC study suggestive of health
benefits for older patients whose TSH levels lie within the
subclinical hypothyroid range, as in this elderly cohort
(mean age 75 years), those with a TSH (4.5–6.99mU/L)
had faster gait speed and superior cardiorespiratory fitness
than those with lower TSH levels. [76] The Leiden 85+
study found no relationship between the serum TSH or fT4
and limitations to activities of daily living in people over the
age of 85 years. [16] In the Zoetermeer study, a longitudinal
population study of independent ambulatory predominantly
euthyroid men, lower T4 and T3 levels were associated
with improved physical functional status. [19] Quality of life
assessment scores have been shown not to differ between
the euthyroid and subclinical hypothyroid groups in an
elderly population. [49]
There is relatively scant evidence on the effects of sub-
clinical hypothyroidism on bone health. A Japanese study
which employed quantitative heel ultrasound reported that
although subclinical hypothyroidism does not appear to
affect bone turnover there was an observed impact on bone
structure. [77] The MrOS study found no association
between TSH and bone loss as measured by sequential hip
dual-energy X-ray absorptiometry, nor an increased
fracture risk in the subclinical hypothyroid or hypothyroid
categories. [78] An American prospective observational
study which followed up a cohort of 3567 people over the
age of 65 years for a median duration of 13 years found that
subclinical hypothyroidism was significantly associated with
increased risk of hip fracture in men with a hazard ratio of
2.31 (95% CI, 1.25–4.27) but not women. [79]
In summary, there is little evidence in the literature to
clearly link overt hypothyroidism with reduced mobility
or increased frailty, and in subclinical hypothyroidism
there is some published data suggestive of improvements
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in these domains compared to euthyroid individuals,
although the data is conflicting here.
Longevity
As the proportion of older people worldwide is increasing
rapidly, the factors associated with healthy ageing have be-
come the focus of intense research. Several theories have
connected ageing with energy metabolism. One such pro-
posed mechanism relates the lifespan of an organism with
its size due to variation in resting metabolic rate. Another
theory proposes that increases in free radicals that are gen-
erated due to oxidative metabolism are associated with the
negative effects of ageing. [80] Thyroid hormones, via its ef-
fects on metabolism and the oxidative stress pathways, play
a crucial role in the process of ageing and longevity. Experi-
mental data effectively demonstrate the correlation between
thyroid hormones and lifespan. Animal models of longevity,
either naturally long-living or genetically modified, demon-
strate low thyroid hormone. [81, 82] Age-related mild
hypofunction of the thyroid gland seems to confer a longev-
ity benefit. Numerous population-based studies have shown
either a survival benefit, [16, 19, 83–85] or no adverse
impact of lower thyroid function. [18]
As thyroid hormones have a direct impact on the meta-
bolic rate of an individual and can thus play a key role in
modulating longevity it is possible that thyroid hormone
replacement in older hypothyroid individuals needs to be
tailored differently to that of younger patients. However,
the target TSH and thyroid hormone levels are uniform
across the age groups and age-specific ranges are not uti-
lised. This is despite the fact that the oldest age groups
comprise the largest proportion of all hypothyroid. [3]
Furthermore, over-treatment with thyroid hormones is
common in older women, which is a risk factor for atrial
fibrillation and osteoporosis. [86] In the United Kingdom,
areas with higher levothyroxine prescribing are independ-
ently associated with atrial fibrillation. [87] No definitive
trial of levothyroxine treatment in elderly hypothyroid pa-
tients comparing different TSH target values is currently
available. A feasibility trial of manipulating thyroid
hormone doses in older hypothyroid patients aiming for a
higher serum TSH level concluded that a definitive trial is
viable. [41]
Treatment of hypothyroidism in the elderly
Despite the high prevalence of hypothyroidism, there have
only been a few RCTs that have investigated outcomes
with levothyroxine replacement. Three small RCTs in
middle aged individuals with subclinical hypothyroidism
showed improvement in cognitive function with levothyr-
oxine replacement therapy. [73, 74, 88] Two larger RCTs
with longer follow up have not shown any benefit in
cognition with levothyroxine replacement, with the latter
study specifically being in the elderly population aged 65
years or over. [49, 75]
The dose of levothyroxine that normalises serum TSH
level is lower in older patients due to changes in thyroxine
turnover with age related reduction in lean body mass.
[89] Other factors such as decreased absorption, concomi-
tant medication use, and other comorbidities could also
affect thyroid hormone metabolism. The elderly are more
susceptible to the ill-effects of thyroid hormone excess
such as AF, [90] and osteoporotic fractures. [91, 92]
Therefore, careful adjustments of levothyroxine dose at
regular intervals are required in this population to avoid
iatrogenic hyperthyroidism. The largest study to date of
12months of levothyroxine treatment in subclinical
hypothyroidism in older persons concluded that there was
no benefit of treatment on quality of life or symptoms.
[93] This double-blind, randomised, placebo-controlled
trial of 737 patients older than 65 years with subclinical
hypothyroidism demonstrated no significant improvement
in the 100-point ThyPRO score (Thyroid-Related Quality
of Life Patient-Reported Outcome) with low-dose
levothyroxine treatment. [93] Therefore, in addition to the
lower dose requirements related to thyroxine metabolism,
based on the current evidence, it is reasonable to raise the
target serum TSH up to 6 or 7mU/L in persons greater
than age 70–80 years particularly if they are at risk of
cardiac arrhythmias or osteoporotic fractures.
Conclusions
Thyroid hormones have an essential role in the functioning
of nearly all tissues in the body at all stages. Thyroid func-
tion changes with age and these alterations are more pro-
nounced at both ends of the life span. Current evidence
suggests that a slight lowering of thyroid function in older
individuals, as evidenced by a marginally raised serum TSH
and low normal FT4, may not be associated with an adverse
outcome and may, in fact, be beneficial. On the other hand,
high thyroid function, as evidenced by a low TSH level
needs careful monitoring and treatment considered if there
is evidence of end-organ damage (such as osteoporosis or
AF), or if serum TSH is suppressed. Despite major ad-
vances in our understanding of thyroid function and ecol-
ogy, mainly due to improvements in assay techniques and
high-quality epidemiological studies, several unresolved
issues remain. It is currently unclear what the precise
underlying mechanisms are behind the changes in thyroid
function that are observed in older individuals. Moreover, it
is uncertain whether these changes are part of healthy aging
or are a bio-marker of underlying disease.
More research is required to fully understand why thy-
roid function changes in older individuals and whether
modulation of thyroid hormones is advantageous for
healthy aging and longevity. Mild thyroid hormone defi-
ciency (or subclinical hypothyroidism) is more common
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in the elderly. But, if it is ‘normal’ and indeed desirable
to have a slightly low thyroid function in older people
then the current use of uniform reference ranges across
all adult ages may need to be revised. Age-specific refer-
ence ranges may be required to diagnose thyroid disease
with special reference to subclinical thyroid disease as
well as to target serum TSH in patients on thyroid hor-
mone replacement. And, in the future, it is possible that
manipulation of thyroid function for health and longev-
ity may be routinely practiced.
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